According to Wall Street, 35 percent this year
Novocure shares have declined significantly this year, partly due to permanent net loss. However, the company is making great clinical and regulatory progress. Although there are certain risks, stocks may increase due to significant catalysts. 10 shares we like more than Novocure › It was a difficult year Novocure (NASDAQ: NVCR)Oncology focused on biotechnology. Since … Read more